Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.

Andrade MC, Oliveira Mde F, Nagao-Dias AT, Coêlho IC, Cândido Dda S, Freitas EC, Coelho HL, Bezerra FS.

Rev Soc Bras Med Trop. 2013 Nov-Dec;46(6):776-8.

2.

The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease.

Ghobadifar MA, Kalani N, Gitiforouz M, Mosallanejad Z.

Rev Soc Bras Med Trop. 2014 Sep-Oct;47(5):669. No abstract available.

3.

Summaries for patients. Long-term outcomes of treating nonacute Chagas disease with benznidazole.

[No authors listed]

Ann Intern Med. 2006 May 16;144(10):I32. No abstract available.

PMID:
16702585
4.

Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.

Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A.

Ann Intern Med. 2006 May 16;144(10):724-34.

PMID:
16702588
5.

Authors' reply: Vitamins in the treatment of chronic Chagas disease: adjuvant antiparasitary or antioxidant therapy?

Andrade MC, Oliveira Mde F, Nagao-Dias AT, Coêlho IC, Cândido Dda S, Freitas EC, Coelho HL, Bezerra FS.

Rev Soc Bras Med Trop. 2014 Sep-Oct;47(5):670-1. No abstract available.

6.
7.

Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Sguassero Y, Cuesta CB, Roberts KN, Hicks E, Comandé D, Ciapponi A, Sosa-Estani S.

PLoS One. 2015 Oct 5;10(10):e0139363. doi: 10.1371/journal.pone.0139363. eCollection 2015. Review.

8.
9.

[Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].

Moretti E, Cervetta L, Basso B, Castro I, Santamarina N.

Bol Chil Parasitol. 1998 Jan-Jun;53(1-2):3-9. Spanish.

PMID:
9830716
10.

Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM.

Lancet. 1996 Nov 23;348(9039):1407-13.

PMID:
8937280
11.

Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission.

Sosa-Estani S, Cura E, Velazquez E, Yampotis C, Segura EL.

Rev Soc Bras Med Trop. 2009 Sep-Oct;42(5):484-7.

12.

Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simões-Barbosa A, Tinoco DL, Teixeira AR.

Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):111-8.

PMID:
11388500
13.

Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease.

Pinto AY, Valente Vda C, Coura JR, Valente SA, Junqueira AC, Santos LC, Ferreira AG Jr, de Macedo RC.

PLoS One. 2013 May 27;8(5):e64450. doi: 10.1371/journal.pone.0064450. Print 2013.

14.

Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.

Fabbro D, Velazquez E, Bizai ML, Denner S, Olivera V, Arias E, Pravia C, Ruiz AM.

Rev Inst Med Trop Sao Paulo. 2013;55(3). pii: S0036-46652013000300167. doi: 10.1590/S0036-46652013000300005.

15.

Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole.

Chippaux JP, Clavijo AN, Santalla JA, Postigo JR, Schneider D, Brutus L.

Trop Med Int Health. 2010 Jan;15(1):87-93. doi: 10.1111/j.1365-3156.2009.02431.x. Epub 2009 Nov 23.

16.

Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study.

Galvao LM, Nunes RM, Cançado JR, Brener Z, Krettli AU.

Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):220-3.

PMID:
8337734
17.

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease.

Fragata-Filho AA, França FF, Fragata Cda S, Lourenço AM, Faccini CC, Costa CA.

PLoS Negl Trop Dis. 2016 Mar 14;10(3):e0004508. doi: 10.1371/journal.pntd.0004508. eCollection 2016 Mar.

18.

Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras.

Escribà JM, Ponce E, Romero Ade D, Viñas PA, Marchiol A, Bassets G, Palma PP, Lima MA, Zúniga C, Ponce C.

Mem Inst Oswaldo Cruz. 2009 Nov;104(7):986-91.

19.

Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment.

Lana Md, Lopes LA, Martins HR, Bahia MT, Machado-de-Assis GF, Wendling AP, Martins-Filho OA, Montoya RA, Dias JC, Albajar-Viñas P, Coura JR.

Mem Inst Oswaldo Cruz. 2009 Dec;104(8):1139-47.

20.

Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease.

Guevara AG, Taibi A, Alava J, Guderian RH, Ouaissi A.

Trans R Soc Trop Med Hyg. 1995 Jul-Aug;89(4):447-8. No abstract available.

PMID:
7570896

Supplemental Content

Support Center